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OPEN
ORIGINAL ARTICLE
Genetic contributions to Trail Making Test performance in
UK Biobank
SP Hagenaars1,2,3,4, SR Cox1,2, WD Hill1,2, G Davies1,2, DCM Liewald1,2, CHARGE consortium Cognitive Working Group, SE Harris1,5,
AM McIntosh1,3, CR Gale1,2,6,7 and IJ Deary1,2,7
The Trail Making Test (TMT) is a widely used test of executive function and has been thought to be strongly associated with general
cognitive function. We examined the genetic architecture of the TMT and its shared genetic aetiology with other tests of cognitive
function in 23 821 participants from UK Biobank. The single-nucleotide polymorphism-based heritability estimates for trail-making
measures were 7.9% (part A), 22.4% (part B) and 17.6% (part B−part A). Signiﬁcant genetic correlations were identiﬁed between
trail-making measures and verbal-numerical reasoning (rg40.6), general cognitive function (rg40.6), processing speed (rg40.7)
and memory (rg40.3). Polygenic proﬁle analysis indicated considerable shared genetic aetiology between trail making, general
cognitive function, processing speed and memory (standardized β between 0.03 and 0.08). These results suggest that trail making is
both phenotypically and genetically strongly associated with general cognitive function and processing speed.
Molecular Psychiatry advance online publication, 19 September 2017; doi:10.1038/mp.2017.189
INTRODUCTION
The Trail Making Test (TMT) is widely used in both research and
clinical settings as a test of some aspects of executive function.1–3
The TMT is usually given as two parts, from which three measures
are derived. In TMT Part A (TMT A), participants are required to
connect an array of numbers in ascending order, by drawing a
continuous line (trail) between them as quickly and accurately as
possible. TMT Part B (TMT B) requires participants to connect an
array of both numbers and letters in alternating ascending order
(1, A, 2, B, 3, C and so on) with the same emphasis on speed and
accuracy (Supplementary Figure 1). Subtracting TMT A completion
time from that of TMT B (TMT B−A) is thought to allow the relative
contributions of visual search and psychomotor speed to be
parsed from the more complex executive functions (such as
cognitive ﬂexibility) required to alternate between numbers and
letters.4–8
TMT performance has been ascribed to a number of cognitive
processes, ‘including attention, visual search and scanning,
sequencing and shifting, psychomotor speed, abstraction, ﬂex-
ibility, ability to execute and modify a plan of action, and ability to
maintain two trains of thought simultaneously’.9 It is considered a
useful tool in research and clinical practice due to the sensitivity of
the task (particularly TMT B and B−A) to frontal lobe damage (in
some, but not other studies10) and dementia.11–13 There are
declines in both TMT A and B performance in ageing.10,14–20 There
is also evidence for performance deﬁcits on TMT B in mood
disorders21 and in patients with schizophrenia and their
relatives18,22–27
Family-based and twin-based studies have provided evidence
for a genetic contribution to individual differences in trail making,
estimating the heritability for trail making part A between 0.23
and 0.38, and between 0.39 and 0.65 for trail making part B.28–30 A
recent genome-wide association study (GWAS) of trail making part
A and part B in a sample of around 6000 individuals did not ﬁnd
any genome-wide signiﬁcant hits;31 however, GWAS of other
cognitive phenotypes have demonstrated that much larger
sample sizes are required to reliably identify signiﬁcant genetic
loci.32,33 Trail making is thought to have genetic inﬂuences that
are shared with other cognitive abilities, with a twin-based genetic
correlation of 0.48 reported between trail making, measured as
the ratio between trail making part A and trail making part B, and
general cognitive function, and 0.52 with working memory.34
In addition to a relatively poor understanding of the molecular
genetic underpinnings of TMT, its cognitive and psychometric
architecture merits further research. Speciﬁcally, it is unclear
whether the cognitive abilities required for TMT B performance are
distinct from other cognitive domains, because TMT A and B
scores correlate with measures of general cognitive function and
processing speed (correlation coefﬁcient estimates range from
~0.3 to ~ 0.7 (refs 9,20)).30,35–38 Evidence from cognitive-ageing
studies further suggests a strong overlap between TMT perfor-
mance and other cognitive domains, because age-related decline
in processing speed and working memory account for much of
the age effects on TMT B.9,20,39,40 However, reliably identifying the
cognitive processes that underpin cognitive test performance
using phenotypic correlational analyses alone is sub-optimal, for
example, refs 41–43. Rather, the interpretation of relationships
between TMT performance and other cognitive abilities such as
general cognitive function, may be enhanced by considering and
comparing their respective shared and unshared causes, including
their genetic architecture. By examining the shared genetic
architecture of TMT and other measures of cognitive ability, the
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current study might aid a better understanding of potential
biological pathways involved in general and speciﬁc cognitive
abilities.
The aim of the present study is to (1) add to the understanding
of the genetic architecture of trail making and (2) to explore the
overlap between genetic architecture of TMT performance and
other cognitive abilities, including general cognitive function.
Although several studies have examined the genetic architecture
of the TMT and its overlap with other cognitive abilities, they had
relatively low power. The largest TMT GWAS (N~ 6000) to date
used a variety of assessments across multiple cohorts across
multiple countries, potentially leading to heterogeneity in both
sample composition and in the cognitive measures.31 The current
study design, using 423 000 UK Biobank participants, mitigates
such confounds: the almost fourfold increase in sample size yields
greater statistical power, and the single sample reduces hetero-
geneity in genetic testing and in phenotype, because all
participants had white British ancestry and took the same TMT
test with the same instructions. In addition, we add to this
signiﬁcantly larger GWAS than has previously been conducted
with (1) estimates of the single-nucleotide polymorphism (SNP)-
based heritability of TMT performance and (2) an examination of
genetic overlap among the different TMT test measures and with
other cognitive functions, using polygenic proﬁle analysis and
genetic correlations in independent samples.
MATERIALS AND METHODS
Participants
UK Biobank is a large resource which aims to identify determinants of
human diseases in middle aged and older individuals (http://www.
ukbiobank.ac.uk).44 A total of 502 655 community-dwelling individuals
aged between 37 and 73 years were recruited in the United Kingdom
between 2006 and 2010. Baseline assessment included cognitive testing,
personality self-report, and physical and mental health measures. For the
present study, genome-wide genotyping data were available for 112 151
participants (58 914 females and 53 237 males) after quality control (see
below). They had a mean (s.d.) age of 56.9 (7.9) years (range 40 to 73 years).
UK Biobank received ethical approval from the Research Ethics Committee
(REC reference for UK Biobank is 11/NW/0382). This study was completed
under UK Biobank application 10279. Figure 1 shows the study ﬂow for the
present study.
Measures
Trail making test. The TMT A and TMT B were introduced at a follow-up
testing wave in UK Biobank, between 2014 and 2015. For TMT A,
participants were instructed to connect numbers (1–25) consecutively
(which were quasi-randomly distributed on the touchscreen) as quickly as
possible in ascending order by selecting the next number. TMT B is similar,
but letters (A–L) and numbers (1–13) had to be selected in alternating
ascending order, for example, 1A 2 B 3 C and so on. The intervals between
touching two points was timed in seconds using a Javascript timer. The
total time (in seconds) to complete the TMT (part A or B) was derived by
summing the interval values between two points. Nine out of 23 821
individuals who scored 4250 s for TMT B were excluded. Owing to
positively skewed distributions, both TMT A and TMT B scores were log-
transformed prior to further analyses. The difference between the raw
scores for TMT A and TMT B was computed as TMT B minus TMT A (TMT
B−A). Fifty-two out of 23 821 individuals with scores o − 50 or 4150
were removed from TMT B−A. After exclusions, 23 822 individuals with
genetic data completed TMT A, 23 812 individuals with genetic data
completed TMT B and 23 769 individuals had complete information for
TMT B−A. The three trail making measures have been scored such that a
higher score indicates better performance. This study also used the verbal-
numerical reasoning (VNR) test from UK Biobank (VNR, N= 36 035), which
consisted of a 13-item questionnaire assessing verbal and arithmetical
deduction (Cronbach α reliability = 0.62) as described by Hagenaars et al.45
Genotyping and quality control
The interim release of UK Biobank included genotype data for 152 729
individuals, of whom 49 979 were genotyped using the UK BiLEVE array
and 102 750 using the UK Biobank axiom array. These arrays have over
95% content in common. Details of the array design, genotyping
procedures and quality control details have been published
elsewhere.45,46 UK Biobank released an imputed dataset as part of the
interim data release. More details can be found at the following URL:
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id = 157020. A minor allele
frequency cutoff of 1% was used for all autosomal variants, as well as an
imputation quality score above 0.3 (N~ 9.7M SNPs).
GWAS analysis
Genotype–phenotype association analyses were conducted using SNPTEST
v2.5.1.47 The ‘frequentist 1’ option was used to specify an additive model
and genotype dosages were analysed to account for genotype uncertainty.
All phenotypes were adjusted for the following covariates before analysis;
age, gender, assessment centre, genotyping array and batch, and the ﬁrst
10 genetic principal components for population stratiﬁcation. The GWAS of
VNR has been performed previously.32
SNP-based heritability and genetic correlations
Univariate GCTA-GREML48 analysis was performed to estimate the
proportion of variance explained by all genotyped common SNPs for
TMT A, TMT B and TMT B−A. To include only unrelated individuals, a
relatedness cutoff of 0.025 was used in the generation of the genetic
relationship matrix. Given the likely difference in reliability between the
raw (TMT A and TMT B) and difference (TMT B−A) scores,49 we undertook
a supplementary analysis to compare reliability-weighted heritability
estimates (see Supplementary Methods) to provide a clearer comparison
of h2 differences between elements of the TMT. Bivariate GCTA-GREML48
and linkage disequilibrium (LD) score regression50 were used to derive
genetic correlations between TMT measures and VNR in UK Biobank.32 LD
score regression was also used to estimate genetic correlations between
trail making measures in UK Biobank and trail making part A, trail making
part B, general cognitive function, processing speed and memory from the
CHARGE consortium (participants aged 45 years or older) meta-analyses of
these cognitive phenotypes.31,33,51
Gene-based association analysis
MAGMA52 was used to derive gene-based associations using the summary
results of the three GWAS for trail making. Genes (18 354) were analysed
after the SNPs were assigned a gene based on their position using the
Completed 
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All recruited participants (N = 502 655)
Interim genetic data release
(N = 152 729)
Genetic data Quality Control (QC) (N = 
112 151)
Completed 
TMT A 
+ QC
(N = 23 822)
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non-British ancestry 
high missingness
relatedness
QC failure in UK 
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gender mismatch
TMT B - A
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(N = 23 769)
Figure 1. Flow diagram of participant selection.
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NCBI 37.3 build, without additional boundaries placed around the genes.
To account for LD, the European 1000 Genomes data panel (phase 1,
release 3) was used as a reference. A Bonferroni correction was used to
control for 18 345 tests (α= 0.05/18 345; Po2.73× 10− 6). The gene-based
associations for trail making were compared with gene-based associations
for VNR and with the gene-based associations for trail making, general
cognitive function, processing speed and memory from the CHARGE
consortium, based on the GWAS summary results.31,33,51 The CHARGE
summary results were converted from HapMap2 to 1000G format, to
ensure the maximum overlap between the two samples. This was achieved
using the LiftOver programme, which converts coordinate ranges between
genome assemblies.
Partitioned heritability
Partitioned heritability analyses were performed on the trail making SNP-
based association results to determine if SNPs group together according to
a speciﬁc biological function or role and thereby making an enriched
contribution to the total proportion of heritability of the trail making
phenotypes. These analyses were performed using the data processing
pipeline as suggested by Finucane et al.53
Polygenic proﬁle analyses
Polygenic proﬁle analyses were performed to predict TMT performance
into UK Biobank and to predict cognitive function scores in two
independent cohorts, Generation Scotland’s Scottish Family Health Study
(GS) and the Lothian Birth Cohort of 1936 (LBC1936). Prediction from the
CHARGE consortium meta-analysis of trail making, general cognitive
function, processing speed and memory into UK Biobank was performed
to test the extent to which individual differences in TMTs in UK Biobank
could be predicted by the polygenic architecture of these four traits.
Polygenic prediction into UK Biobank. The UK Biobank genotyping data
were recoded from numeric (1,2) allele coding to standard ACGT coding
using a bespoke programme developed by one of the present authors
(DCL).45 Polygenic proﬁle scores were created for trail making part A, trail
making part B, general cognitive function, processing speed and memory
based on the results from the CHARGE consortium meta-analysis in all
genotyped participants using PRSice.54 SNPs with a minor allele
frequencyo0.01 were removed before creating the scores. Clumping
was used to obtain SNPs in LD with an r2o0.25 within a 250 kb window.
Five polygenic proﬁles were created for each of the three phenotypes
according to the signiﬁcance of the association with the trail making
phenotype, at P-value thresholds of 0.01, 0.05, 0.1, 0.5 and 1 (all LD pruned
SNPs). Regression models were used to examine the association between
the polygenic proﬁles and TMT A, TMT B and TMT B−A phenotype scores
in UK Biobank, adjusting for age at measurement, sex, genotyping batch
and array, assessment centre and the ﬁrst 10 genetic principal components
for population stratiﬁcation. All associations were corrected for multiple
testing using the false discovery rate method.55
Polygenic prediction into GS and LBC1936. Polygenic proﬁle scores were
created in PRSice,54 using the UK Biobank trail making SNP-based
association results, for genotyped participants of GS (n= 19 994, mean
(s.d.) age = 47.18 (15.10) years) and LBC1936 (n=1005, mean (s.d.) age of
72.55 (0.7) years for all tests, except trail making part B, which was tested at
a mean (s.d.) age of 76.30 (0.68) years). Individuals were removed from GS
if they had contributed to both UK Biobank and GS (n=174). Polygenic
proﬁle scores were created based on the signiﬁcance of the association in
UK Biobank with the trail making phenotype, at P-value thresholds of 0.01,
0.05, 0.1, 0.5 and 1 (all SNPs). Linear regression models were created to test
the association between the polygenic proﬁles for trail making and the
target phenotypes in: GS (Wechsler digit-symbol substitution,56 phonemic
verbal ﬂuency,1 Wechsler logical memory,57 the Mill Hill vocabulary test,58
a ﬂuid cognitive function component and a general cognitive function
component) and in LBC1936 (trail making part B, a ﬂuid cognitive function
component, vocabulary, memory, processing speed, change in ﬂuid
cognitive function between age 11 years and age 70 years, Moray House
Test score at age 11 years and Moray House Test score at age 70 years).
Further details about the cognitive tests can be found in the
Supplementary Materials. All models were adjusted for age, sex and the
ﬁrst ﬁve (GS) or four (LBC1936) principal components for population
stratiﬁcation. The GS models were also adjusted for family structure by
ﬁtting a univariate linear mixed model, which estimates the genetic and
environmental variance, using the ASReml programme.59 All associations
were corrected for multiple testing using the false discovery rate
method.55
Meta-analysis
Inverse variance-weighted meta-analysis of UK Biobank trail making and
CHARGE trail making GWAS was performed using the METAL package
(http://www.sph.umich.edu/csg/abecasis/Metal). The meta-analysis was
restricted to SNPs that were available in both samples (N SNPs TMT
A=2 332 746; N SNPs TMT B=2 466 810) and the samples did not include
any overlapping individuals. The total sample in the meta-analysis
consisted of 29 251 individuals for TMT A and 30 022 for TMT B.
Code availability
The code used to run the analysis is available from the authors upon
request.
RESULTS
Phenotypic correlations
A total of 23 822 individuals with genetic data completed TMT A,
23 812 individuals with genetic data completed TMT B and 23 769
individuals with genetic data had complete information for TMT
B−A. Table 1 shows the phenotypic correlations between the TMT
phenotypes, as well as with VNR in UK Biobank. Correlations
indicated that individuals who took more time to complete the
TMTs had lower performance on the VNR test. The strongest
correlation between VNR and TMT was found for TMT B (0.36).
Supplementary Figure 2 shows the age and sex distribution of the
different trail making measures.
Genome-wide association study
The results of the GWAS analyses are presented in Figure 2; for
each trail making phenotype, a Manhattan and a Q–Q plot
are shown.
TMT part A. For TMT A, no SNPs reached genome-wide
signiﬁcance. Gene-based analyses identiﬁed three genes that
were signiﬁcantly associated with TMT A (Table 2 and
Supplementary Table 1a); CRNKL1, a protein necessary for pre-
mRNA splicing on chromosome 20;60 caspase 5 (CASP5), which has
a role in the execution phase of cell apoptosis on chromosome
11;61 and NAA20, a component of the N-acetyltransferase complex
B on chromosome 20.62 All three of these genes were also
nominally signiﬁcant (Po0.05) in the GWAS of TMT B and CASP5
was also nominally signiﬁcant in the analyses for CHARGE general
cognitive function and processing speed (Table 2).
The proportion of variance in TMT A explained by all common
genetic variants using GCTA-GREML was 0.079 (SE 0.024).
Table 1. Phenotypic correlations for the UK Biobank cognitive tests in
all genotyped participants
TMT A TMT B TMT B−A VNR
TMT A −
TMT B 0.62 (0.004) −
TMT B−A 0.04 (0.006) 0.80 (0.002) −
VNR 0.20 (0.010) 0.36 (0.009) 0.32 (0.010) −
Abbreviations: TMT A, Trail Making part A; TMT B, Trail Making part B; TMT
B−A, Trail Making part B−part A; VNR, verbal-numerical reasoning. The s.e.
for the correlations are shown in parentheses. Pearson’s correlations
were used for continuous–continuous correlations for the phenotypic
correlations.
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TMT part B. One SNP exhibited genome-wide signiﬁcance for
TMT B, on chromosome 1 (rs34804445, P= 4.18 × 10− 8, MAF=
0.0253). This SNP was not located within a gene. Gene-based
analyses identiﬁed one gene (PUM1 on chromosome 1) associated
with TMT B (Table 2 and Supplementary Table 1b); this gene
regulates ATAXIN1 and is associated with neurodegeneration.63
This gene was also nominally signiﬁcant (Po0.05) in the gene-
based analysis for the other trail making variables measured in UK
Biobank. Results for this gene were not available for the CHARGE
consortium phenotypes (Table 2).
The proportion of variance in TMT B explained by all common
genetic variants using GCTA-GREML was 0.224 (s.e. 0.026).
Figure 2. Manhattan and Q–Q plot of P-values of the single-nucleotide polymorphism (SNP)-based association analysis of Trail Making Part A,
Trail Making Part B and Trail Making Part B− Part A. The red line in the Manhattan plots indicates the threshold for genome-wide signiﬁcance
(Po5 × 10− 8); the grey line indicates the threshold for suggestive signiﬁcance (Po1 × 10− 5).
Genetic contributions to TMT performance
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TMT part B− A. No SNPs reached genome-wide signiﬁcance for
TMT B−A. Gene-based analyses did not identify any signiﬁcant
associations for TMT B−A (Supplementary Table 1c).
The proportion of variance in TMT B−A explained by all
common genetic variants using GCTA-GREML was 0.176 (s.e.
0.025). Heritability estimates and s.e. of all three TMT measures,
weighted according to estimates of their reliabilities, are reported
in Supplementary Table 2. They indicate that the ostensible
difference in h2 between TMT B and TMT B−A could possibly be
attributed to differences in reliability.
Partitioned heritability
Signiﬁcant enrichment was found for TMT B in evolutionary
conserved regions with a 500 bp boundary, where 33% of the
SNPs accounted for 95% of the heritability (enrichment metric =
2.85, s.e. = 0.44, P= 2.42 × 10− 5). TMT A and TMT B−A were
unsuitable for this analysis, due to low heritability Z-scores, which
were 2.6 and 5.4, respectively.53
Genetic correlations
The results of the bivariate GCTA-GREML and LD score regression
analyses within UK Biobank are shown in Table 3. The LD score
regression analyses with the cognitive phenotypes from the
CHARGE consortium are shown in Table 4. Strong positive genetic
correlations, using GCTA-GREML, were observed between all three
measures derived from the TMT in UK Biobank (rg between 0.64
and 0.96). Large genetic correlations were found between the
three TMTs and VNR (rg between 0.59 and 0.64). Similar results
were found when calculating the genetic correlations using LD
score regression (Table 3). Positive genetic correlations were
observed between trail making in UK Biobank and the following
GWAS meta-analyses from the CHARGE consortium: general
cognitive function (rg between 0.61 and 0.70), processing speed
(rg between 0.69 and 0.76) and memory (rg between 0.29 and
0.35) (Table 4). The conﬁdence interval for the associations
between TMT and general cognitive function, and between TMT
and processing speed did not overlap with the conﬁdence interval
for the association between TMT and memory.
Polygenic prediction
Polygenic proﬁles based on the TMT A summary results from the
CHARGE consortium signiﬁcantly predicted all three TMTs in UK
Biobank (β between 0.016 and 0.029, Table 5). Polygenic proﬁles
based on the TMT B summary results from the CHARGE
consortium signiﬁcantly predicted all three TMTs in UK Biobank
(β between 0.024 and 0.036, Table 5). The strongest associations
for the other cognitive test polygenic proﬁles (general cognitive
function, processing speed and memory) were found for general
cognitive function polygenic proﬁles predicting TMT B in UK
Biobank, explaining 0.67% of the variance. The full results
including all thresholds can be found in Supplementary Table 3a.
The GWAS results for the three trail making phenotypes in UK
Biobank were used to create polygenic proﬁle scores in two
independent cohorts: GS and the LBC1936 (Figure 3 and
Supplementary Tables 3b and 3c). The polygenic proﬁles for
TMT A signiﬁcantly predicted digit-symbol substitution, verbal
ﬂuency, Mill Hill vocabulary, ﬂuid cognitive function and general
cognitive function in GS (β between 0.018 and 0.039). In the
LBC1936, the polygenic proﬁles for TMT A signiﬁcantly predicted
trail making part B (β= 0.102), ﬂuid cognitive function, memory
and change in ﬂuid cognitive function (β between 0.079 and
0.094). Signiﬁcant predictions were observed across almost all
thresholds for TMT B and TMT B−A for the cognitive phenotypes
measured in GS. In LBC1936, polygenic proﬁles for TMT B and TMT
B−A were both signiﬁcantly associated with ﬂuid cognitive
function, processing speed, cognitive function at age 11 years
and cognitive function at age 70 years. TMT B was also
signiﬁcantly associated with trail making part B, memory and
change in ﬂuid cognitive function between age 11 years and age
70 years. The strongest association in GS was found between the
polygenic proﬁle for TMT B and Wechsler digit symbol substitu-
tion; this association explained 0.53% of the variance, at an SNP
inclusion threshold of all SNPs from the GWAS. The largest
proportion of variance explained in LBC1936 was 1.75% for trail
making part B using the TMT B polygenic score with an SNP
inclusion threshold of all SNPs from the GWAS. The complete
results can be found in Supplementary Tables 3b and c.
Meta-analysis
In the meta-analysis of the combined dataset (UK Biobank and
CHARGE, combined N TMT A= 29 251, combined N TMT B= 30
022), no genome-wide signiﬁcant SNPs were observed for TMT A
or TMT B (Supplementary Figure 3). The one genome-wide
Table 2. Gene-based results showing genome-wide signiﬁcant genes for TMTA and TMT B, and corresponding signiﬁcance values for other TMT and
cognitive measures in UK Biobank and CHARGE
UK Biobank phenotypes CHARGE consortium phenotypes
Gene CHR TMT A TMT B TMT B−A VNR TMT A TMT B General cognitive function Processing speed Memory
CRNKL1 20 2.94×10−7 0.0009 0.3764 0.0433 0.9802 0.7963 0.3308 0.7839 0.2171
CASP5 11 2.06×10−6 0.0105 0.7079 0.6030 0.0909 0.5916 0.0116 0.0331 0.8928
NAA20 20 1.84×10−6 0.0033 0.5590 0.1628 0.9266 0.7289 0.2176 0.6251 0.4307
PUM1 1 0.0413 4.92×10−8 9.03× 10− 5 0.9461 NA NA NA NA NA
Abbreviations: NA, not applicable; TMT A, Trail Making part A; TMT B, Trail Making part B; TMT B−A, Trail Making part B−part A; VNR, verbal-numerical
reasoning. Unmodiﬁed P-values are shown for all phenotypes. Genome-wide signiﬁcant P-values (FDR r2.73 × 10− 6) are shown in bold.
Table 3. Genetic correlations (s.e.) using GCTA-GREML (under
diagonal) and LD score regression (above diagonal) for the TMTs and
verbal-numerical reasoning in UK Biobank
TMT A TMT B TMT B−A VNR
TMT A − 0.921 (0.07) 0.827 (0.17) 0.558 (0.11)
TMT B 0.840 (0.09) − 0.981 (0.03) 0.767 (0.07)
TMT B−A 0.640 (0.19) 0.958 (0.03) − 0.793 (0.10)
VNR 0.589 (0.36) 0.636 (0.14) 0.587 (0.18) −
Abbreviations: LD, linkage disequilibrium; TMT A, Trail Making part A;
TMT B, Trail Making part B; TMT B−A, Trail Making part B−part A; VNR,
verbal-numerical reasoning.
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signiﬁcant hit identiﬁed in this study for TMT B was not available
in CHARGE.
DISCUSSION
This study ﬁnds one genome-wide signiﬁcant variant associated
with TMT part B performance in UK Biobank, and provides the ﬁrst
SNP-based heritability estimates for the three widely used TMT
measures. We identiﬁed high genetic correlations between trail
making, VNR, general cognitive function and processing speed,
and somewhat lower genetic correlations with memory. Using
only common SNPs to create a polygenic score for TMT B, we were
able, at best, to predict ~ 2% of the variance in trail making part B
in LBC1936. Taken together, these analyses point to a considerable
degree of shared polygenic architecture for TMT performance with
general cognitive function and processing speed measures, in
particular. The results are consistent with the hypothesis that trail
making is genetically and phenotypically similar to general ﬂuid
cognitive function.9,20,34
Univariate GCTA-GREML analyses suggested SNP-based herit-
ability estimates for TMT A, TMT B and TMT B−A of 8%, 22% and
18%, respectively. These provide a ﬁrst estimate of the contribu-
tion of common SNPs to the phenotype of trail making and
suggest that common SNPs account for around half of the
additive genetic variation for trail making, based on twin and
family studies.30 SNP-based heritability studies for other complex
traits also report similar differences between SNP-based and
pedigree-based heritability.48,64 Twin and family studies estimate
heritability based on all causal variants, both common and rare,
whereas SNP-based studies estimate heritability only on geno-
typed SNPs in LD with causal variants. It is possible that causal
variants have lower minor allele frequencies than the genotyped
SNPs, leading to incomplete LD between unknown causal variants
and genotyped SNPs.65
Previous studies of the genetic overlap between trail making
and other cognitive abilities have shown genetic overlap between
trail making and general cognitive function using a twin
design.30,34 Our results add to this by using a molecular genetic
design and showing shared genetic aetiology between trail
making and verbal numerical reasoning in UK Biobank, as well
as with general cognitive function, processing speed, and memory
from the CHARGE consortium. The estimates of the genetic
correlations within UK Biobank were similar for both GCTA-GREML
and LDS regression, suggesting that these results are unlikely to
constitute false positives.
We also used polygenic proﬁle scores to estimate the genetic
overlap between TMT and other cognitive abilities. First, we
created polygenic proﬁles based on the CHARGE consortium
summary GWAS data (including trail making, general cognitive
function, processing speed and memory) and found that the
polygenic proﬁle for general cognitive function was the best
predictor of all TMT scores in UK Biobank compared with either of
the other polygenic proﬁles. The unequal sample sizes from which
the polygenic proﬁle scores were derived (TMT~ 6000; general
cognitive function ~ 54 000; processing speed~ 32 000,
memory ~ 29 000) may have led to an underestimation of the
ability of CHARGE TMT score to predict UK Biobank TMT test
performance.
The genetic association between TMT and other cognitive
measures could be due to an overall halo-effect of general
cognitive ability. Although the current study does not allow us to
test this empirically, we note that the respective polygenic
associations between TMT and ﬂuid cognitive ability in GS and
LBC1936, as well as the genetic correlations between TMT and
VNR, do point to this halo-effect. Future studies could expand
these ﬁndings by removing the variance speciﬁc to general
cognitive ability from the associations between TMT and other
measures of cognitive ability.
Our combined meta-analysis of UK Biobank and CHARGE trail
making did not yield any signiﬁcant SNPs. This could be ascribed
to the following factors. The SNPs for the CHARGE consortium are
imputed to the HAPMAP 2 reference panel (N~ 2M SNPs), whereas
the UK Biobank sample is imputed to a combination of the UK10
haplotype and the 1000G reference panel (N~ 17M SNPs). For TMT
A 2 332 746 SNPs overlapped between UK Biobank and CHARGE
and for TMT B 2 466 810 SNPs overlapped between the two
samples. The SNP that reached genome-wide signiﬁcance in the
UK Biobank GWAS was not available in CHARGE.
In addition to those discussed above, our study has other
limitations. There are currently no reliability data available for the
TMT version administered in UK Biobank. Although the computer-
based version was based upon standard administration protocols,
the current absence of such data necessitates that these results be
interpreted with appropriate caution. The measure of ﬂuid
cognitive function provided by UK Biobank (which we have called
VNR) showed a relatively modest age-related trajectory, in contrast
to the steeper and well-replicated age-related decline that would
be expected for this construct66,67 (Supplementary Figure 4). This
may partly explain the relatively modest correlation of VNR with
TMT performance, when compared to those previously reported9
and may have also had a bearing on our analyses of genetic
overlap within UK Biobank. In addition, the UK Biobank sample did
not have sufﬁcient breadth of contemporaneously-administered
standardized/validated cognitive tests to be able to construct a
robust measure of general cognitive function (such as in other
large samples9,20,68). This limited our ability to perform a more
detailed analysis of the phenotypic or genetic overlap between
trail making and general cognitive function in UK Biobank itself.
This study has several strengths. It has the largest single sample
size to date of a GWAS for trail making, offering greater statistical
power while excluding bias caused by sample or phenotypic
heterogeneity. Population stratiﬁcation was minimized by only
using individuals of white British ancestry. This study shows the
ﬁrst estimates of the heritability for TMT using molecular genetic
Table 4. Genetic correlations (s.e.), derived using LD score regression, between three TMT in UK Biobank and general cognitive function, processing
speed and memory from the CHARGE consortium
TMT A TMT B TMB B−A
rg s.e. P rg s.e. P rg s.e. P
General cognitive function 0.6076 0.11 2.73× 10−8 0.6951 0.07 3.02× 10−22 0.6566 0.08 9.84× 10−15
Processing speed 0.7614 0.15 3.01× 10−7 0.7646 0.08 7.69× 10−20 0.6877 0.10 8.36× 10−13
Memory 0.2945 0.14 0.0404 0.3532 0.09 0.0001 0.2994 0.11 0.0055
Abbreviations: LD, linkage disequilibrium; TMT A, Trail Making part A; TMT B, Trail Making part B; TMT B−A, Trail Making part B−part A. Tests that survived
false discovery rate correction (P= 0.0404) are shown in bold.
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data uses a comprehensive battery of techniques to examine
genetic architecture of TMT and used the same TMT and
administration protocol across the whole sample. The use of both
GWAS summary data from the CHARGE consortium, and the
prediction of the UK Biobank TMT GWAS into GS and LBC1936
cognitive phenotypes allowed a detailed examination of the
shared genetic aetiology between TMT and cognitive phenotypes.
These strengths have enabled a detailed characterization of the
shared genetic aetiology between performance on TMT and other
cognitive abilities. Our results, spanning methodologies and
cohorts, provide strong evidence for a shared genetic aetiology
between TMT performance and general cognitive function and
processing speed, which are themselves strongly phenotypically
and genetically correlated. When the full genetic data from UK
Biobank on half a million individuals becomes available, it would
enable robust replication and extensions of the current ﬁndings.
More detailed cognitive testing is planned for UK Biobank, and
these data can be used in future studies to further examine the
genetic overlap between TMT and other cognitive functions.
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Figure 3. Heat map of associations between the polygenic proﬁle
scores for trail making in UK Biobank and cognitive function in
Generation Scotland (GS) and the Lothian Birth Cohort 1936
(LBC1936). *False discovery rate (FDR)-corrected signiﬁcant associa-
tions (FDR corrected P-value o = 0.029 (GS) or 0.025 (LBC1936)).
Further information can be found in Supplementary Tables 2b and c.
Age 11 MHT score, age 11 Moray House Test score; Age 70 MHT
score, age 70 Moray House Test score; Vocabulary (MHV), Mill Hill
Vocabulary test; Vocabulary (NART), National Adult Reading Test;
LBC1936, Lothian Birth Cohort 1936; TMT A, Trail Making Test part A;
TMT B, Trail Making Test part B; TMT B−A, Trail Making Test part
B− Trail Making Test part A; Stand. β, standardized β.
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